Compare PARR & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PARR | OGN |
|---|---|---|
| Founded | 1984 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2000 | 2020 |
| Metric | PARR | OGN |
|---|---|---|
| Price | $53.93 | $6.41 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $48.80 | $11.75 |
| AVG Volume (30 Days) | 1.3M | ★ 3.7M |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | ★ 1313.56 | N/A |
| EPS | ★ 7.16 | 0.72 |
| Revenue | $2,443,066,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.42 |
| Revenue Next Year | $4.98 | $1.67 |
| P/E Ratio | ★ $7.42 | $8.79 |
| Revenue Growth | ★ 30.99 | N/A |
| 52 Week Low | $12.04 | $6.18 |
| 52 Week High | $54.23 | $15.88 |
| Indicator | PARR | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 73.24 | 32.12 |
| Support Level | $33.67 | $6.18 |
| Resistance Level | N/A | $7.87 |
| Average True Range (ATR) | 2.44 | 0.26 |
| MACD | 0.81 | -0.07 |
| Stochastic Oscillator | 98.58 | 7.15 |
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.